サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1785858

ブロックバスターオンコロジーブランドの世界市場

Blockbuster Oncology Brands

出版日
ページ情報
英文 284 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
ブロックバスターオンコロジーブランドの世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 284 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ブロックバスターオンコロジーブランドの世界市場は2030年までに643億米ドルに到達

2024年に429億米ドルと推定されるブロックバスターオンコロジーブランドの世界市場は、2024～2030年の分析期間においてCAGR 7.0％で成長し、2030年には643億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである肺がんは、CAGR7.9%を記録し、分析期間終了時には327億米ドルに達すると予測されます。乳がん分野の成長率は、分析期間中CAGR 6.8%と推定されます。

米国市場は推定117億米ドル、中国はCAGR11.1％で成長予測

米国のブロックバスターオンコロジーブランド市場は2024年に117億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに135億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と6.8%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界のブロックバスターオンコロジーブランド市場- 主要動向と促進要因のまとめ

ブロックバスターオンコロジーブランドががん治療市場を独占している理由とは？

ブロックバスターオンコロジーブランドは、患者の予後を大幅に改善する標的を絞った非常に効果的な治療を提供し、現代のがん治療の要として台頭してきました。世界のがん罹患率の上昇と、がん治療薬開発への投資の増加が相まって、複数のがん種に優れた有効性で対処できる高度な治療薬への需要が高まっています。製薬大手は、がん領域を重要な治療領域として優先しており、免疫チェックポイント阻害剤、標的治療薬、個別化医療アプローチなどの画期的な薬剤の導入につながっています。これらのブランドは大きな市場シェアを獲得しているだけでなく、がん領域における臨床革新のベンチマークとなっています。ブロックバスターオンコロジーブランドの成功の主な理由の一つは、精密医療を活用する能力です。がん細胞と健康な細胞の両方を無差別に攻撃する従来の化学療法とは異なり、標的療法はがん細胞に関連する特定の分子マーカーや遺伝子マーカーに焦点を当てる。このアプローチにより、治療効果を最大化しながら副作用を最小限に抑えることができるため、腫瘍内科医と患者の双方にとって好ましい選択肢となっています。ヘルスケアプロバイダーが個別化された治療計画を重視するにつれて、こうした高性能のオンコロジーブランドに対する需要は加速し、市場での優位性はさらに強固なものになると予想されます。

技術の進歩はがん治療薬市場をどのように形成しているか？

バイオテクノロジーとゲノム研究の進歩は、ブロックバスターオンコロジーブランドの進化において極めて重要な役割を果たしています。次世代シーケンシング（NGS）とバイオマーカー主導型の医薬品開発により、製薬企業は個々のがんプロファイルに極めて特異的な治療法を設計できるようになりました。このプレシジョン・オンコロジーへのシフトは、毒性や治療抵抗性を低減しながら、患者の予後を改善する標的治療の創出につながります。さらに、AIを活用した創薬により、新たながん治療薬の開発と試験に要する時間が大幅に短縮され、規制当局による承認への道のりが加速しています。オンコロジー市場におけるもう一つの大きな技術的変化は、免疫療法の台頭です。PD-1阻害剤やCTLA-4阻害剤のようなチェックポイント阻害剤は、がんと闘うために身体の免疫システムを利用することによって、がん治療を一変させました。さらに、CAR-T細胞療法は血液悪性腫瘍の治療における画期的なアプローチとして注目を集めています。これらの進歩は生存率を向上させるだけでなく、以前は選択肢が限られていた患者の治療選択肢を広げています。製薬企業が免疫療法と標的治療を統合した併用療法への投資を続ける中、ブロックバスターオンコロジーブランド市場は飛躍的な成長を遂げると思われます。

ブロックバスターオンコロジーブランドの拡大を牽引する市場動向とは？

がん治療薬市場は、治療効果と患者中心のアウトカムが薬価と採用を決定する、価値に基づく治療へのシフトを目の当たりにしています。政府やヘルスケア機関は、がん治療薬の費用対効果をますます重視するようになっており、製薬会社は臨床的価値の高い治療法の開発に注力するようになっています。この動向により、アウトカムに基づく価格設定モデルや、有効性の高いがん治療薬の使用を奨励する償還構造が拡大しています。市場を形成するもう一つの主要動向は、バイオシミラーの採用拡大です。大ヒットしたがん治療薬の特許が切れるにつれ、バイオシミラー医薬品の競合が激化し、治療費の引き下げと患者へのアクセシビリティの向上が期待されます。しかし、バイオシミラーの課題にもかかわらず、主要ながん治療薬ブランドは、継続的な技術革新、ライフサイクル管理戦略、コンパニオン診断アプリケーションを拡大するための診断企業との戦略的提携を通じて、市場の優位性を維持し続けています。さらに、遠隔患者モニタリングやAI主導の治療推奨を含むデジタルヘルス技術の台頭は、大ヒットしたがん治療薬の有効性をさらに最適化しつつあります。

ブロックバスターオンコロジーブランド市場の主な成長促進要因は？

ブロックバスターオンコロジーブランド市場の成長は、世界のがん負担の増加、標的治療や免疫治療における継続的な技術革新、画期的ながん治療に対する規制当局の承認拡大など、いくつかの要因によってもたらされます。バイオマーカー主導の医薬品開発が統合されたことで、製薬会社は特定のがん種に合わせた非常に効果的な治療法を開発できるようになり、市場の成長はさらに強まっています。さらに、複数の薬剤が相乗的に作用して治療効果を高める併用療法の台頭が、ブロックバスターオンコロジーブランドの需要を促進しています。また、個々の患者に最適な治療を特定するコンパニオン診断薬の採用が拡大していることも、市場拡大の推進に重要な役割を果たしています。さらに、ゲノム研究やAIを活用した創薬の進歩に支えられた個別化医療や精密腫瘍学へのシフトが、この分野の持続的成長を確実なものにしています。がん研究開発への投資が増加し続け、ヘルスケアインフラが世界的に改善するにつれて、ブロックバスターオンコロジーブランド市場は今後数年間、力強く安定した拡大が見込まれます。

セグメント

治療タイプ（肺がん、乳がん、多発性骨髄腫、リンパ腫、その他の治療タイプ）、流通チャネル（病院薬局、小売薬局、その他の流通チャネル）

調査対象企業の例

  • Amgen Inc.
  • Ascendis Pharma A/S
  • AstraZeneca
  • Bayer's Pharmaceuticals
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Leapfrog Bio
  • Pfizer Inc.
  • pharmaand GmbH
  • Vidac Pharma

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29635

Global Blockbuster Oncology Brands Market to Reach US$64.3 Billion by 2030

The global market for Blockbuster Oncology Brands estimated at US$42.9 Billion in the year 2024, is expected to reach US$64.3 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Lung Cancer, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$32.7 Billion by the end of the analysis period. Growth in the Breast Cancer segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.7 Billion While China is Forecast to Grow at 11.1% CAGR

The Blockbuster Oncology Brands market in the U.S. is estimated at US$11.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.5 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Blockbuster Oncology Brands Market - Key Trends & Drivers Summarized

Why Are Blockbuster Oncology Brands Dominating the Cancer Treatment Market?

Blockbuster oncology brands have emerged as a cornerstone of modern cancer treatment, offering targeted and highly effective therapies that significantly improve patient outcomes. The rise in global cancer prevalence, coupled with increased investment in oncology drug development, has driven the demand for advanced therapeutics that can address multiple cancer types with superior efficacy. Pharmaceutical giants are prioritizing oncology as a key therapeutic area, leading to the introduction of groundbreaking drugs, including immune checkpoint inhibitors, targeted therapies, and personalized medicine approaches. These brands not only command significant market share but also set the benchmark for clinical innovation in the oncology space. One of the primary reasons for the success of blockbuster oncology brands is their ability to leverage precision medicine. Unlike traditional chemotherapy, which indiscriminately attacks both cancerous and healthy cells, targeted therapies focus on specific molecular and genetic markers associated with cancer cells. This approach minimizes side effects while maximizing treatment effectiveness, making it a preferred choice for both oncologists and patients. As healthcare providers emphasize personalized treatment plans, demand for these high-performing oncology brands is expected to accelerate, further solidifying their dominance in the market.

How Are Technological Advancements Reshaping the Oncology Drug Market?

Advancements in biotechnology and genomic research are playing a pivotal role in the evolution of blockbuster oncology brands. Next-generation sequencing (NGS) and biomarker-driven drug development have enabled pharmaceutical companies to design therapies that are highly specific to individual cancer profiles. This shift toward precision oncology is leading to the creation of targeted therapies that deliver better patient outcomes while reducing toxicity and treatment resistance. Furthermore, AI-powered drug discovery is significantly shortening the time required to develop and test new oncology drugs, accelerating their path to regulatory approval. Another major technological shift in the oncology market is the rise of immunotherapies. Checkpoint inhibitors such as PD-1 and CTLA-4 inhibitors have transformed cancer treatment by harnessing the body's immune system to fight cancer. Additionally, CAR-T cell therapy has gained traction as a revolutionary approach for treating hematologic malignancies. These advancements are not only improving survival rates but also expanding treatment options for patients who previously had limited choices. As pharmaceutical companies continue investing in combination therapies that integrate immunotherapy with targeted treatments, the market for blockbuster oncology brands is poised for exponential growth.

What Market Trends Are Driving the Expansion of Blockbuster Oncology Brands?

The oncology drug market is witnessing a shift toward value-based care, where treatment effectiveness and patient-centric outcomes determine drug pricing and adoption. Governments and healthcare agencies are increasingly emphasizing the cost-effectiveness of oncology drugs, prompting pharmaceutical companies to focus on developing therapies with high clinical value. This trend has led to the expansion of outcome-based pricing models and reimbursement structures that incentivize the use of highly effective oncology brands. Another key trend shaping the market is the growing adoption of biosimilars. As patents for blockbuster oncology drugs expire, biosimilar competition is expected to intensify, driving down treatment costs and increasing accessibility for patients. However, despite biosimilar challenges, leading oncology brands continue to maintain market dominance through continuous innovation, lifecycle management strategies, and strategic partnerships with diagnostic firms to expand companion diagnostic applications. Additionally, the rise of digital health technologies, including remote patient monitoring and AI-driven treatment recommendations, is further optimizing the efficacy of blockbuster oncology therapies.

What Are the Key Growth Drivers for the Blockbuster Oncology Brands Market?

The growth in the Blockbuster Oncology Brands market is driven by several factors, including the increasing global cancer burden, continuous innovation in targeted and immunotherapies, and expanding regulatory approvals for breakthrough oncology treatments. The integration of biomarker-driven drug development is enabling pharmaceutical companies to create highly effective therapies tailored to specific cancer types, further strengthening market growth. Additionally, the rise of combination therapies, where multiple drugs work synergistically to enhance treatment efficacy, is fueling demand for blockbuster oncology brands. The growing adoption of companion diagnostics, which help identify the most suitable treatments for individual patients, is also playing a crucial role in driving market expansion. Furthermore, the shift toward personalized medicine and precision oncology, supported by advancements in genomic research and AI-powered drug discovery, is ensuring sustained growth in this segment. As investment in oncology R&D continues to rise and healthcare infrastructure improves globally, the blockbuster oncology brands market is set to witness strong and steady expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Blockbuster Oncology Brands market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma, Other Treatment Types); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Amgen Inc.
  • Ascendis Pharma A/S
  • AstraZeneca
  • Bayer's Pharmaceuticals
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Leapfrog Bio
  • Pfizer Inc.
  • pharmaand GmbH
  • Vidac Pharma

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Blockbuster Oncology Brands - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Cancer Incidence Drives Sustained Demand for High-Efficacy Oncology Therapeutics
    • Breakthrough Innovations in Immunotherapy and Targeted Therapies Propel Market Expansion of Blockbusters
    • Regulatory Accelerated Approval Pathways Strengthen Business Case for First-Mover Advantage in Oncology
    • Biopharma R&D Investment and Strategic Alliances Accelerate Drug Discovery for Novel Cancer Targets
    • Clinical Success and Overall Survival Benefit Data Propel Market Confidence in Leading Oncology Brands
    • Personalized Medicine and Biomarker-Based Therapies Expand Addressable Patient Populations
    • High Market Penetration in Developed Economies Sustains Revenue Streams for Top Oncology Brands
    • Strategic Label Expansion and New Indication Approvals Drive Lifecycle Extension of Blockbuster Drugs
    • Oncology-Focused M&A Activity Throws Spotlight on Market Consolidation and Brand Synergies
    • Digital Health and Companion Diagnostics Integration Strengthens Treatment Monitoring and Adoption
    • Intellectual Property Protection and Patent Extensions Sustain Exclusivity for Leading Brands
    • Pipeline Diversification and Portfolio Management Strategies Sustain Revenue Amidst Competitive Pressure
    • Growing Role of Real-World Evidence and Post-Market Studies Enhances Market Position of Blockbusters
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blockbuster Oncology Brands Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blockbuster Oncology Brands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Blockbuster Oncology Brands by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Blockbuster Oncology Brands by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Blockbuster Oncology Brands by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Blockbuster Oncology Brands by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION